Medison Expands its Partnership with Albireo to Commercialize Odevixibat in Canada and Israel for Cholestatic Liver Diseases
- Medison & Albireo expands its collaboration to a multi-regional agreement to commercialize Odevixibat in Canada and Israel for the treatment of rare cholestatic liver diseases
- The collaboration helps to enhance Albireo's global commercial strategy and increases access to new markets for its innovative treatment. The collaboration also provides innovative solutions to patients suffering from rare cholestatic liver diseases
- Odevixibat has been approved in the EU as Bylvay for the treatment of all types of PFIC in patients aged ≥6mos. Additionally, Bylvay has been approved in the US for the treatment of pruritus in patients aged ≥3mos. with all types of PFIC
Ref: PR Newswire | Image: Medison Pharma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.